COMT Val158Met Polymorphism and Catecholamine Methylation

Genetic Determinants of Neurotransmitter and Oestrogen Metabolism — A Literature Review

Magdalena Behensky[1], René Rohrmanstorfer[1], Thomas Dullnig[1], Daniel Wallerstorfer[1]

[1]*Laboratory, Novogenia GmbH, Salzburg, Austria*

Corresponding Author: Daniel Wallerstorfer (ceo@novogenia.com)

ABSTRACT

Background. **Catechol-O-methyltransferase (COMT) is the major enzyme that methylates catecholamines (dopamine, noradrenaline, adrenaline) and catechol oestrogens, using SAM as methyl donor. The common Val158Met polymorphism (rs4680) substantially modifies COMT activity: the Met158 allele produces a thermolabile enzyme with approximately one-quarter of wild-type activity. This modifies prefrontal dopamine levels, executive function and working memory (the 'warrior–worrier' phenotype), catechol-oestrogen clearance, and the methylation-cycle load of neurotransmitter handling.**

Methods. **Focused literature review of COMT Val158Met in neuropsychiatric, oestrogen-related and methylation-cycle contexts.**

Results. **Met158 homozygotes (approximately 25 % of European-descent individuals) have higher baseline prefrontal dopamine and are associated with better executive function under low cognitive load but greater vulnerability under stress. Val158 homozygotes (approximately 25 %) show opposite pattern. Met158 has been associated with modest increases in risk of oestrogen-related cancers in some cohorts, consistent with slower clearance of catechol oestrogens.**

Discussion. **COMT is a major SAM-consuming enzyme, so adequate methionine and methylation-cycle support (folate, B12, B6, B2, magnesium) is important for sustained catecholamine and catechol-oestrogen methylation. In Met158 carriers with high sympathetic load, supporting methyl-donor availability and moderating stimulant intake (caffeine in slow CYP1A2 metabolisers, amphetamines, stress) can be clinically useful.**

Subjects: Genetics, Methylation, Neuroscience. **Keywords:** COMT; rs4680; Val158Met; catecholamines; dopamine; methylation; catechol oestrogens.

INTRODUCTION

COMT is a major enzyme of catecholamine inactivation in the central nervous system and periphery. It methylates the 3-hydroxyl group of catechol substrates — dopamine, noradrenaline, adrenaline and catechol oestrogens — using SAM as the methyl donor.

COMT is particularly important in the prefrontal cortex, where the dopamine reuptake transporter is sparse and enzymatic catabolism dominates dopamine clearance.

The Val158Met polymorphism (rs4680, c.472G>A) substitutes methionine for valine at position 158 of the membrane-bound COMT isoform. The Met allele produces a thermolabile enzyme with approximately 25 % of wild-type activity (Lachman et al., 1996). This three-fold difference in COMT activity between homozygous genotypes has substantial consequences for prefrontal dopamine levels, cognitive function under stress, and the rate of catechol-oestrogen clearance.

COMT VAL158MET — MECHANISM AND CONSEQUENCES

The Met158 allele frequency is approximately 50 % in European-descent populations, with approximately 25 % of individuals Met/Met (low-activity), 50 % heterozygous and 25 % Val/Val (high-activity). Met/Met carriers have higher basal prefrontal dopamine, perform better on executive-function tasks under low cognitive load, and are better characterised by reflective, planning-oriented cognition — the so-called 'worrier' phenotype. Val/Val carriers clear dopamine faster, maintain cognition better under high stress/cognitive load but show slightly poorer baseline executive function — the 'warrior' phenotype.

In the oestrogen-metabolism domain, COMT methylates catechol oestrogens to less reactive methoxy-oestrogens. Met/Met carriers clear catechol oestrogens more slowly, which — together with variants in CYP1B1 and oestrogen-receptor genes — has been associated in some cohorts with modestly increased risk of oestrogen-related cancers. Effect sizes are modest and context-dependent.

TABLE 1 — SUPPORTING HUMAN STUDIES

STUDY (AUTHOR, YEAR)	POPULATION	DESIGN · SNP / FOCUS	PRIMARY OUTCOME / KEY FINDINGS
Lachman et al., 1996	**Population:** Human tissue samples.	**Design:** Functional characterisation. **SNP:** COMT Val158Met (rs4680).	Met158 allele produces a thermolabile enzyme with approximately 25 % of wild-type activity — the foundational functional characterisation of COMT Val158Met (Lachman et al., 1996).
Egan et al., 2001	**Population:** Healthy adults and patients with schizophrenia.	**Design:** Neuroimaging and cognitive study. **SNP:** COMT Val158Met.	Val/Val genotype was associated with less efficient prefrontal cortical function on executive tasks; Met/Met performed better on working memory tasks (Egan et al., 2001).
Savitz et al., 2006	**Population:** Literature review.	**Design:** Review. **Focus:** COMT and mood/cognition.	Synthesised evidence that COMT Val158Met modulates dopaminergic function, mood regulation and executive function; established the warrior–worrier framework (Savitz et al., 2006).

STUDY (AUTHOR, YEAR)	POPULATION	DESIGN · SNP / FOCUS	PRIMARY OUTCOME / KEY FINDINGS
Goodman et al., 2001	**Population:** Breast-cancer case–control studies.	**Design:** Case–control study. **SNP:** COMT Val158Met.	Met/Met genotype was associated with modestly increased breast-cancer risk in post-menopausal women, consistent with slower catechol-oestrogen clearance (Goodman et al., 2001).
Gene–environment interaction studies	**Population:** Healthy adults and clinical populations.	**Design:** Stress–cognition studies. **Focus:** COMT Val158Met × cognitive load/stress.	Cognitive performance interaction with genotype: Met/Met performs better at baseline, Val/Val maintains performance better under high stress/cognitive load, reinforcing the context-dependent nature of COMT-related phenotypes.

INTERVENTION RATIONALE

COMT is a major SAM-consuming enzyme, so adequate methylation-cycle support is a logical strategy for sustained catecholamine and catechol-oestrogen methylation — particularly in Met/Met carriers with slower enzyme kinetics. Methylfolate, methylcobalamin, P-5-P, riboflavin, betaine and magnesium collectively support the supply of SAM. Adequate protein intake supplies methionine.

Lifestyle factors matter. Met/Met carriers may be more sensitive to stimulants (caffeine, especially in slow CYP1A2 metabolisers; amphetamines; high-intensity stress), which impose additional methylation demand. Stress-management practice, adequate sleep and moderate exercise optimise dopaminergic function. For post-menopausal women with Met/Met genotype, emphasising cruciferous vegetables (which upregulate catechol-oestrogen methylation pathways) and maintaining healthy body weight (since adipose tissue is a major source of peripheral oestrogens) is a coherent prevention strategy.

OPEN QUESTIONS

The context-dependent nature of COMT effects makes broad recommendations difficult. Genotype-stratified trials of methylation support, cognitive interventions and oestrogen-related cancer prevention are limited. The interaction between COMT and other dopaminergic, adrenergic and oestrogen-metabolism variants is an active research area.

CONCLUSION

COMT Val158Met is one of the most extensively studied functional polymorphisms in psychiatric, cognitive and oestrogen-metabolism genetics. Met/Met and Val/Val homozygotes show context-dependent advantages and vulnerabilities. Adequate methylation-cycle support (methylfolate, methylcobalamin, P-5-P, riboflavin, betaine, magnesium), balanced stimulant intake, and attention to catechol-oestrogen metabolism — particularly in Met/Met carriers — form a coherent genotype-informed nutritional and lifestyle strategy.

REFERENCES

1. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995 May;10(1):111–3. PMID: 7647779.
2. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab. 1998 Nov;64(3):169–72. PMID: 9719624.
3. van der Put NM, Gabreëls F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet. 1998 May;62(5):1044–51. PMID: 9545395.
4. Wilson A, Platt R, Wu Q, Leclerc D, Christensen B, Yang H, et al. A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Mol Genet Metab. 1999 Aug;67(4):317–23. PMID: 10444343.
5. Leclerc D, Campeau E, Goyette P, Adjalla CE, Christensen B, Ross M, et al. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet. 1996 Dec;5(12):1867–74. PMID: 8968741.
6. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996 Jun;6(3):243–50. PMID: 8807664.
7. McNulty H, Dowey le RC, Strain JJ, Dunne A, Ward M, Molloy AM, et al. Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C→T polymorphism. Circulation. 2006 Jan 3;113(1):74–80. PMID: 16380549.
8. Tsang BL, Devine OJ, Cordero AM, Marchetta CM, Mulinare J, Mersereau P, et al. Assessing the association between the methylenetetrahydrofolate reductase (MTHFR) 677C>T polymorphism and blood folate concentrations: a systematic review and meta-analysis. Am J Clin Nutr. 2015 Jun;101(6):1286–94. PMID: 26497154.
9. Raghubeer S, Matsha TE. Methylenetetrahydrofolate (MTHFR), the one-carbon cycle, and cardiovascular risks. Nutrients. 2021 Dec 20;13(12):4562. PMID: 34960114.